The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I dose-escalation study to evaluate safety and feasibility of neoadjuvant camrelizumab with palbociclib for the treatment of resectable esophageal squamous cell carcinoma (ESCC).
 
Shangwei Sun
No Relationships to Disclose
 
Yang Hu
No Relationships to Disclose
 
Ling Lan
No Relationships to Disclose
 
Yang Li
No Relationships to Disclose
 
Zhong Wu
No Relationships to Disclose
 
Jiehui Deng
No Relationships to Disclose
 
Adam Bass
Employment - Novartis Institutes of Biomedical Research
Stock and Other Ownership Interests - Signet Therapeutics
Consulting or Advisory Role - Earli; HelixNano
Research Funding - Bayer; Merck; Novartis; Repare Therapeutics
 
Yahui Zhao
No Relationships to Disclose
 
Zhihua Liu
No Relationships to Disclose
 
Jin Zhou
No Relationships to Disclose